Synthase of (-)-gemmarene A and preparation method thereof
By providing (-)-gemane A synthase with high homology proteins and expressing the enzyme in yeast or E. coli, the problem of (-)-gemane A synthase deficiency in the prior art is solved, and the problem of (-)-gemane A synthase is achieved. Efficient production of (-)-β-elene.
Patent Information
- Application Number
- CN202310642542.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-01
- Publication Date
- 2024-12-03
AI Technical Summary
The synthase of (-)-gemane A is difficult to synthesize in the prior art, resulting in low production efficiency of (-)-β-elene and relatively lack of research.
Provided a synthetase of (-)-Gemalene A, derived from the genus Micromonosporus for catalyzing farni The radical pyrophosphate produces (-)-gemane A and expresses the enzyme in yeast or E. coli by recombinant vectors and transgenic techniques.
Achieve efficient production of (-)-gemane A, improve the yield and production efficiency of (-)-beta-elene, and fill the gap in the lack of (-)-gemane A synthase in the prior art .
Smart Images

Figure SMS_3 
Figure SMS_4 
Figure SMS_5
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and relates to a synthase of (-)-germaene A and a preparation method thereof. Background Art
[0002] β-elemene is a volatile sesquiterpenoid compound with a tulip flavor. As a national Class II new drug, its oral emulsion and injection have achieved significant clinical therapeutic effects.
[0003] At present, the biological pathway generates the sesquiterpenoid compound Germacrene A through the catalysis of the precursor substance Farnesyl pyrophosphate (FPP) by Germacrene A synthase (GAS). Germacrene A can directly obtain β-elemene through a simple Cope rearrangement in vitro.
[0004] GAS is widely distributed in plants and microorganisms. Currently, many studies have been conducted to express GAS in recombinant engineering bacteria for the synthesis of (+)-germane A, and the corresponding Cope rearrangement product is (-)-β-elemene. However, researchers have discovered the existence of (+)-β-elemene (Research Progress on Analysis, Detection Methods and Preparation Technology of β-elemene, Huang Hanchang), as shown in Compound I: The corresponding precursor compound is (-)-germane A, as shown in compound II: However, the synthase that synthesizes (-)-germazine A has rarely been reported. Summary of the invention
[0005] The invention provides a (-)-germaene A synthase for producing (-)-germaene A, which is used for producing (+)-β-elemene through a biological pathway.
[0006] The present invention provides a protein, comprising a sequence selected from the following: 1) a sequence having at least 62% homology, preferably at least 63% homology, preferably at least 66% homology, preferably 99% homology to the amino acid sequence shown in SEQ ID NO.6; 2) or a sequence obtained by substituting and / or deleting, or adding / reducing one or more amino acids in the sequence shown in SEQ ID NO.6; 3) or a fusion protein obtained by connecting a tag to the N-terminus or C-terminus of the protein shown in SEQ ID NO.6.
[0007] Further, the protein is derived from Micromonospora, preferably from Micromonospora aurea, Micromonospora deserticola, Micromonospora CB01531, Micromonospora marina, and more preferably from Micromonospora aurea, Micromonospora deserticola, Micromonospora CB01531. The source refers to the different original source hosts of the gene.
[0008] Furthermore, the protein sequence is as shown in SEQ ID NO.6, SEQ ID NO.8, SEQ ID NO.4, or a sequence obtained by replacing and / or deleting, or adding / reducing one or more amino acids from the sequences shown in SEQ ID NO.6, SEQ ID NO.8, SEQ ID NO.4.
[0009] The present invention further provides a nucleic acid molecule for expressing the above-mentioned protein, comprising a sequence selected from the following: 1) a sequence having at least 68% homology, preferably at least 69% homology, preferably at least 71% homology, preferably 99% homology to the nucleotide sequence shown in SEQ ID NO.5; 2) or a sequence obtained by replacing and / or deleting, or adding / reducing one or more nucleotides from the sequence shown in SEQ ID NO.5; 3) or a different transcript or homologous gene sequence produced by the nucleotide sequence shown in SEQ ID NO.5.
[0010] Furthermore, the nucleic acid molecule sequence is shown as SEQ ID NO.5, SEQ ID NO.7, and SEQ ID NO.3.
[0011] Furthermore, the present invention provides a biological material related to any of the nucleotides and proteins described above, wherein the related biological material is any of the following:
[0012] A1) An expression cassette containing the above-mentioned nucleic acid molecule; preferably, the expression cassette comprises a promoter, the above-mentioned nucleic acid molecule and a terminator; preferably, the promoter is selected from TEF1 and PGK1, and the terminator is selected from CYC1 and ADH1.
[0013] A2) a host cell containing the nucleic acid molecule or any of the proteins described above or an expression cassette containing the nucleic acid molecule or comprising the recombinant vector; or,
[0014] A4) A recombinant vector, characterized in that the recombinant vector contains the above-mentioned nucleic acid molecule or expresses the above-mentioned encoding nucleic acid molecule, preferably the recombinant vector includes a promoter, the above-mentioned nucleic acid molecule and a terminator; preferably the promoter is selected from TEF1 and PGK1, and the terminator is selected from CYC1 and ADH1; preferably the recombinant vector sequence is shown in SEQ ID NO.9-13.
[0015] A5) A transgenic plant comprising the above nucleic acid molecule or the above protein or the expression cassette or the recombinant vector or the host cell.
[0016] Furthermore, the present invention provides the use of any of the above-mentioned nucleotide sequences, protein sequences or related biological materials to catalyze the production of (-)-germaene A using farnesyl pyrophosphate (FPP) as a substrate.
[0017] Furthermore, the present invention provides a method for producing (-)-gemaene A, characterized in that the method comprises:
[0018] 1) Provide farnesyl pyrophosphate (FPP) precursor,
[0019] 2) contacting the FPP precursor with an enzyme, wherein the enzyme is used for catalyzing the FPP precursor to generate (-)-germarene A, and the enzyme is selected from the above-mentioned proteins.
[0020] Furthermore, the enzyme is an enzyme in a microorganism that provides a precursor heterologously.
[0021] Furthermore, the microorganism is yeast or Escherichia coli.
[0022] The present invention further provides a genetically modified host cell capable of producing (-)-germane A, comprising 1) one or more heterologous nucleic acids encoding one or more enzymes in the mevalonate pathway for producing farnesyl pyrophosphate; and 2) a heterologous nucleic acid encoding an enzyme for producing (-)-germane A, wherein the enzyme is selected from the above-mentioned protein. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 Plasmid pESC-LEU-P PGK1 -P TEF1 -ERG20-T CYC1 Schematic diagram
[0024] Figure 2 Schematic diagram of plasmid pCDF-glnAP2
[0025] Figure 3 Schematic diagram of plasmid pLacUV5-MVA
[0026] Figure 4 For pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -MaGAS-T ADH1 Schematic diagram
[0027] Figure 5 For pESC-LEU-P TEF1-ERG20-T CYC1 -P PGK1 -MdeTPS-T ADH1 Schematic diagram
[0028] Figure 6 For pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -MmsTPS-T ADH1 Schematic diagram
[0029] Figure 7 For pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -MmGAS-T ADH1 Schematic diagram
[0030] Figure 8 Schematic diagram of pCDF-glnAP2-MaGAS
[0031] Specific implementation examples
[0032] The technical solution of the present invention is further described in detail below in conjunction with the accompanying drawings and specific implementation examples, but the implementation of the present invention is not limited thereto. The equivalent replacement, combination, improvement or modification of the technical solution of the present invention made by those skilled in the art based on the description of the present invention should be included in the protection scope of the present invention.
[0033] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents and materials used in the following examples are commercially available. In the following examples, the pET-28a vector used was purchased from Beijing Liuhe BGI Technology Co., Ltd.
[0034] In the following examples, the fermentation product detection method is as follows:
[0035] Transfer the fermented bacterial liquid to 50mL centrifuge tubes, centrifuge to absorb an appropriate amount of n-dodecane in the upper layer, dilute it 10 times with ethanol, and detect it by GC-MS. Detection instrument: Agilent gas-mass spectrometer 7890B / 5977B. Chromatographic conditions: chromatographic column Agilent CycloSil-B (30m*0.25mm, 0.25μm), injection port temperature 250℃, injection volume 1μL, no splitting, carrier gas He, flow rate 2.3mL / min, column temperature program as shown in Table 1,
[0036] Table 1
[0037]
[0038]
[0039] Mass spectrometry conditions: EI ion source temperature 230 °C, quadrupole temperature 150 °C, electron energy 70 eV, scanning range 50-300 m / z.
[0040] Example 1 Screening of Germaene A Synthase (GAS) from Different Species
[0041] According to the amino acid sequence of the terpene synthase MmGAS from Micromonospora marina in the NCBI database (its nucleotide sequence is shown in SEQ ID NO.1, and its amino acid sequence is shown in SEQ ID NO.2), MaGAS (amino acid sequence is shown in SEQ ID NO.4), MdeTPS (amino acid sequence is shown in SEQ ID NO.6), and MmsTPS (amino acid sequence is shown in SEQ ID NO.8) were obtained. Beijing Liuhe BGI Gene Technology Co., Ltd. optimized and synthesized the gene according to the codons of Escherichia coli or Saccharomyces cerevisiae, and the optimized nucleotide sequence was inserted into the pET-28a vector or the yeast expression vector pESC-LEU-P PGK1 -P TEF1 -ERG20-T CYC1 (Refer to Figure 1 , Figure 4-Figure 7 Schematic diagram using conventional methods), prepared
[0042] pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -MaGAS-T ADH1 (SEQ ID NO.9), pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -MdeTPS-T ADH1 (SEQ ID NO.10), pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -MmsTPS-T ADH1 (SEQ ID NO.11) and pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -MmGAS-T ADH1 (SEQ ID NO.12). The names of the screened and synthesized genes and their annotation information in the database are shown in Table 2.
[0043] Table 2 Enzyme nomenclature and origin
[0044]
[0045]
[0046] Example 2 Construction of yeast recombinant engineering bacteria
[0047] 2.1 Construction of Saccharomyces cerevisiae CEN11 strain
[0048] In order to realize the synthesis of germaene A in Saccharomyces cerevisiae, CEN.PK2-1D was selected for transformation, and gene editing was performed as shown in Table 3 below to finally obtain the Saccharomyces cerevisiae CEN11 strain.
[0049] Table 3
[0050]
[0051]
[0052] 2.2 Preparation of competent CEN11 yeast
[0053] The CEN11 monoclone was picked up and transferred to 3 mL Synthetic Dropout Media (SD-His Ura) liquid culture medium and cultured at 30°C for 24 h. After being transferred to 50 mL Synthetic Dropout Media (SD-His Ura) liquid culture medium at a transfer volume of 5%, the cells were cultured until OD600 = 0.6-0.8, and the cells were collected and chemical transformation competent cells were prepared using the ZYMO Frozen-EZ Yeast TransformationII Kit.
[0054] 2.3 Construction of CEN11-GAS strain
[0055] Take the competent cells in 2.2 above and add plasmids
[0056] pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -MaGAS-T ADH1 , pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -MdeTPS-T ADH1 , pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -MmsTPS-T ADH1 , pESC-LEU-P TEF1 -ERG20-T CYC1 -PPGK1 -MmGAS-T ADH1 , transformed using ZYMO Frozen-EZ Yeast Transformation II Kit, shaken and mixed, incubated at 30℃ for 45min, shaken once every 15 minutes. Spread on Synthetic Dropout Media (SD-His Ura) plate, cultured at 30℃ for 2 days to obtain single clones. The obtained engineered bacteria were named CEN11-MaGAS, CEN11-MdeTPS, CEN11-MmsTPS, and CEN11-MmGAS.
[0057] Example 3 Yeast system yield verification
[0058] 1) The yeast fermentation medium was prepared according to Example 3 of the prior art CN108060092B, and the amino acid content was adjusted appropriately.
[0059] 2) Saccharomyces cerevisiae engineered bacteria fermentation
[0060] The engineered bacteria obtained in Example 2.3 were selected and transferred to 3 mL Synthetic Dropout Media (SD-His Ura) liquid culture medium, and cultured at 30°C, 250 rpm for 24 h; the bacterial solution cultured for 24 h was transferred to a 250 mL Erlenmeyer flask containing 20 mL fermentation medium and 2 mL n-dodecane at a transfer volume of 5%, and cultured at 30°C, 250 rpm for 120 h. The yield test was performed, and the test results are shown in Table 4:
[0061] Table 4
[0062] Engineering bacteria (+)-β-elemene production in yeast (mg / L) CEN11-MaGAS 47.01 CEN11-MdeTPS 13.16 CEN11-MmsTPS 2.41 CEN11-MmGAS 0.45
[0063] Example 4 Construction of pCDF-glnAP2-MaGAS recombinant plasmid
[0064] The constructed plasmid pCDF-glnAP2 (refer to Figure 2 Schematic diagram) was used as a template for reverse amplification to obtain a linear vector, and the synthesized pET-28a-MaGAS plasmid was used as a template to amplify the target fragment containing the homology arm. The detailed information of the primers used is shown in Table 5.
[0065] Use high success rate PCR enzyme TOYOBO KOD FX for fragment amplification. 25μL amplification system: 2×PCRBuffer 12.5μL, 2mM dNTPs 5μL, primers 0.75μL each, template 10ng, KOD FX 0.5μL, add ddH2O to a total volume of 25μL. pCDF-glnAP2 fragment amplification conditions: 94℃ pre-denaturation 5min (1 cycle); 98℃ denaturation 10s, 53℃ annealing 30s, 68℃ extension 2.5min (30 cycles); 68℃ extension 2min (1 cycle). The amplification conditions of MaGAS fragment were as follows: pre-denaturation at 94°C for 5 min (1 cycle); denaturation at 98°C for 10 s, annealing at 60°C for 30 s, and extension at 68°C for 1 min, with the annealing temperature decreasing by 1°C in each subsequent cycle until it reached 50°C, for a total of 10 cycles; denaturation at 98°C for 10 s, annealing at 50°C for 30 s, and extension at 68°C for 1 min (20 cycles); and extension at 68°C for 2 min (1 cycle).
[0066] Table 5 Primer sequences
[0067]
[0068] After the reaction, the fragments were digested with DpnI at 37°C for 2 h, and then electrophoresed on 1% agarose gel. The target fragments were recovered by cutting the gel. -Basic Seamless Cloning and Assembly Kit was used to homologously recombine the linear vector pCDF-glnAP2 with the target fragment of MaGAS, and then transformed into the full-gold Trans 5α competent cells, spread on LB-Spec resistance plates, and cultured at 37°C overnight. Single clones were picked for colony PCR verification using primers glnAP2-check-F and pCDF-check-R (see Table 5), and positive clones were inoculated for culture, and then plasmids were extracted and sent to Beijing Qingke Biotechnology Co., Ltd. for sequencing. The successfully constructed plasmid was named pCDF-glnAP2-MaGAS (refer to Figure 8 Schematic diagram, see SEQ ID NO.13).
[0069] Example 5 Construction of recombinant Escherichia coli
[0070] 5.1 Construction of Escherichia coli W3110L strain
[0071] In order to realize the synthesis of germaene A in Escherichia coli, Escherichia coli W3110 was selected for transformation, and gene editing was performed as shown in Table 6 to obtain Escherichia coli W3110L strain.
[0072] Table 6
[0073] Species name Basic Information Culture medium W3110 F-lambda-IN(rrnD-rrnE)1rph-1 LB W3110L W3110,Δ(glnL) LB
[0074] 5.2 Preparation of competent E. coli W3110L
[0075] The W3110L single clone was cultured in LB liquid medium at 37°C and 250 rpm overnight, and then transferred to 50 mL LB liquid medium at 1% transfer volume until OD600 = 0.4-0.6, and the cells were collected to prepare electroporation competent cells.
[0076] 5.3 Construction of W3110L-MVA-GAS strain
[0077] Take W3110L competent cells and add the constructed plasmid pLacUV5-MVA (refer to Figure 3 Schematic diagram: Prepared by conventional methods, see SEQ ID NO.14), then add the plasmid pCDF-glnAP2-MaGAS constructed in Example 4, mix and transfer to an electroporation cup, electroporation conditions: 1.8KV, 25uF, 200Ω, add 1mL 37℃ preheated SOC after electroporation, resuspend, transfer to a centrifuge tube, recover at 37℃ for 1 hour, spread on LB-Spec+Chlor resistance plate, and culture at 37℃ overnight. The obtained engineered bacteria were named W3110L-MVA-MaGAS.
[0078] Example 6 Escherichia coli system production verification
[0079] 1) Preparation of fermentation medium: Prepare M9 medium according to conventional methods.
[0080] 2) Escherichia coli engineered bacteria fermentation: The engineered bacteria obtained in Example 5.3 were selected and transferred to 3 mL LB-Spec+Chlor liquid medium, and cultured overnight at 37°C and 250 rpm; the bacterial solution cultured overnight was transferred to 20 mL M9 medium and 2 mL n-dodecane in a 250 mL Erlenmeyer flask at a transfer volume of 5%, and cultured at 37°C and 250 rpm for 24 h. The yield was tested. The results are shown in Table 7:
[0081] Table 7
[0082] Engineering bacteria (+)-β-elemene production in E. coli (mg / L) W3110L-MVA-MaGAS 61.07
Claims
1. A protein for producing (-)-germaene A, characterized in that It comprises a sequence selected from the following: 1) a sequence having at least 62% homology, preferably 99% homology, to the amino acid sequence shown in SEQ ID NO.6; 2) or a sequence obtained by replacing and / or deleting, or adding / reducing one or more amino acids from the sequence shown in SEQ ID NO.6; 3) or a fusion protein obtained by connecting a tag to the N-terminus or C-terminus of the protein shown in SEQ ID NO.
6.
2. The protein according to claim 1, characterized in that The protein is derived from the genus Micromonospora, preferably from Micromonospora aurea, Micromonospora deserticola, Micromonospora CB01531, and Micromonospora pieris, and more preferably from Micromonospora aurea, Micromonospora deserticola, and Micromonospora CB01531.
3. The protein according to claim 1, characterized in that The protein sequences are shown in SEQ ID NO.6, SEQ ID NO.8 and SEQ ID NO.
4.
4. A nucleic acid molecule expressing the protein of claim 1, characterized in that: It contains a sequence selected from the following: 1) a sequence having at least 68% homology, preferably 99% homology, to the nucleotide sequence shown in SEQ ID NO.5; 2) or a sequence obtained by replacing and / or deleting, or adding / reducing one or more nucleotides from the sequence shown in SEQ ID NO.5; 3) or a different transcript or homologous gene sequence produced by the nucleotide sequence shown in SEQ ID NO.
5.
5. The nucleic acid molecule according to claim 4, characterized in that The nucleic acid molecule sequences are shown in SEQ ID NO.5, SEQ ID NO.7 and SEQ ID NO.
3.
6. The biological material related to nucleotides and proteins according to any one of claims 1 and 5, characterized in that: The relevant biological material is any of the following: A1) An expression cassette containing the isolated nucleic acid molecule according to claim 5; preferably, the expression cassette comprises a promoter, the isolated nucleic acid molecule according to claim 5 and a terminator; preferably, the promoter is selected from TEF1 and PGK1, and the terminator is selected from CYC1 and ADH1. A2) A host cell comprising the nucleic acid molecule of claim 5 or the isolated protein of any one of claim 2 or an expression cassette containing the isolated nucleic acid molecule or comprising the recombinant vector; or, A4) A recombinant vector, characterized in that the recombinant vector comprises the nucleic acid molecule according to claim 5, preferably the recombinant vector comprises a promoter, the nucleic acid molecule according to claim 5 and a terminator; preferably the promoter is selected from TEF1 and PGK1, and the terminator is selected from CYC1 and ADH1; preferably the sequence of the recombinant vector is as shown in SEQ ID NO.9-13. A5) A transgenic plant comprising the nucleic acid molecule according to claim 5 or the protein according to claim 1 or the expression cassette or the recombinant vector or the host cell.
7. Use of the nucleotide sequence, protein sequence or related biological material according to any one of claims 1 to 6 to catalyze the production of (-)-germaene A using farnesyl pyrophosphate (FPP) as a substrate.
8. A method for producing (-)-germane A, characterized in that The method comprises 1) Provide farnesyl pyrophosphate (FPP) precursor, 2) contacting the FPP precursor with an enzyme, wherein the enzyme is used to catalyze the generation of (-)-germarene A from the FPP precursor.
9. The method according to claim 8, characterized in that The enzyme is selected from the protein according to any one of claims 1 to 3.
10. The method according to claim 8, characterized in that The enzyme is an enzyme in a microorganism that provides a precursor heterologously. The method according to claim 8 , wherein the microorganism is yeast or Escherichia coli.
12. A genetically modified host cell capable of producing (-)-germaene A, characterized in that: 1) one or more heterologous nucleic acids encoding one or more enzymes for producing farnesyl pyrophosphate in the mevalonate pathway; and 2) a heterologous nucleic acid encoding an enzyme for producing (-)-germarene A, wherein the enzyme is selected from the protein of any one of claims 1-3.
Citation Information
Patent Citations
A recombinant bacterium and its uses
CN108060092B
